Abstract
Both the SARS-CoV-2 virus and its mRNA vaccines depend on RNA polymerases (RNAP)1,2; however, these enzymes are inherently error-prone and can introduce variants into the RNA3. To understand SARS-CoV-2 evolution and vaccine efficacy, it is critical to identify the extent and distribution of errors introduced by the RNAPs involved in each process. Current methods lack the sensitivity and specificity to measure de novo RNA variants in low input samples like viral isolates3. Here, we determine the frequency and nature of RNA errors in both SARS-CoV-2 and its vaccine using a targeted Accurate RNA Consensus sequencing method (tARC-seq). We found that the viral RNA-dependent RNAP (RdRp) makes ~1 error every 10,000 nucleotides – higher than previous estimates4. We also observed that RNA variants are not randomly distributed across the genome but are associated with certain genomic features and genes, such as S (Spike). tARC-seq captured a number of large insertions, deletions and complex mutations that can be modeled through non-programmed RdRp template switching. This template switching feature of RdRp explains many key genetic changes observed during the evolution of different lineages worldwide, including Omicron. Further sequencing of the Pfizer-BioNTech COVID-19 vaccine revealed an RNA variant frequency of ~1 in 5,000, meaning most of the vaccine transcripts produced in vitro by T7 phage RNAP harbor a variant. These results demonstrate the extraordinary genetic diversity of viral populations and the heterogeneous nature of an mRNA vaccine fueled by RNAP inaccuracy. Along with functional studies and pandemic data, tARC-seq variant spectra can inform models to predict how SARS-CoV-2 may evolve. Finally, our results may help improve future vaccine development and study design as mRNA therapies continue to gain traction.
Since the COVID-19 pandemic began, we have witnessed the repeated emergence of new SARS-CoV-2 lineages and viral variants of concern (VOC) with the potential to escape vaccine protection. mRNA vaccines based on the Spike protein have been widely used to prevent COVID-19 illness and have been shown to elicit a protective immune response against VOCs after multiple doses5,6. Both SARS-CoV-2 and the mRNA vaccines rely on viral RNA polymerases (RNAPs) for their respective replication or synthesis. RNAPs misincorporate nucleotides at much higher frequencies than their DNA counterparts3, generating RNA variants during synthesis which can fuel viral evolution. The mutation frequency of RNA viruses ranges from 10−4 to 10−6 per base7. SARS-CoV-2 is commonly believed to acquire mutations more slowly than other RNA viruses due to the proofreading activity of its exonuclease during RNA synthesis8. However, to this point, no empirical studies have directly measured the frequency of RdRp errors during replication (Extended Data Fig. 1a), which is a key parameter for modeling virus evolution. Similarly, the nature and frequency of RNA variants generated during vaccine synthesis remains unknown (Extended Data Fig. 1b).
Technical artifacts introduced during library preparation and next generation sequencing (NGS) pose a major challenge to RNA variant detection. To remove these artifacts, new methods that combine RNA-seq with aspects of circle sequencing and molecular barcoding were developed (ARC-seq) to enable accurate variant calling9,10. While these advances in consensus sequencing have reduced technical noise, they typically require considerable substrate (≥1 μg of RNA) and are not feasible for low input samples11. Another major constraint is that variant discovery is directly correlated with sequencing depth, and depth can be difficult to achieve for rare transcripts or organisms with large and complex genomes. To overcome these limitations, we developed targeted Accurate RNA Consensus sequencing (tARC-seq) (Fig. 1). tARC-seq combines the basic features of ARC-seq with hybrid capture technology for target enrichment to enable deep variant interrogation of low input SARS-CoV-2 samples.
tARC-seq validation in E. coli
We first validated tARC-seq in Escherichia coli, where hybrid capture produced a >30-fold enrichment on average in unique consensus reads across a panel of twelve genes (Extended Data Fig. 2). This enrichment allows us to make high confidence measurements of variant frequencies by gene, depending on baseline expression levels.
RNA variants in WT SARS-CoV-2
We next used tARC-seq to examine SARS-CoV-2 RNA isolated from infected Vero cells. Since the yield is low, E. coli mRNA was added during library preparation to serve as a carrier. With hybrid capture some carrier RNA and host sequences are found in the final library; these can be analyzed separately and serve as internal technical controls. When aligned to the E. coli genome, these off-target reads recapitulate the known variant frequency for bulk E. coli mRNA (Fig. 2a)12.
Using tARC-seq, we achieved on average >16,000X depth in consensus reads across the 29,903-nucleotide genome of WT SARS-CoV-2. Positions were filtered for ≥50X depth, which excluded only 0.1% of the genome. Clonal and subclonal variants present at >5% allele frequency were discounted to enrich for de novo events (Extended Data Fig. 3a, Supplementary Table 1). We determined that three or more cDNA copies (i.e. minimum family size) was sufficient to filter out most technical artifacts during consensus calling without compromising read depth (Extended Data Fig. 3b). The overall RNA variant frequency in WT virus was 1.16 × 10−4, or approximately one in 10,000 nucleotides, meaning new virions harbor on average three novel mutations each (Fig. 2b). These de novo variants arise from RdRp errors during genome replication. Host RNA editing by enzymes like APOBECs may also contribute, as evidenced by the elevated frequency of C>T transitions (Fig. 2c and Extended Data Fig. 4)13. Expectedly, most variants are base substitutions (8.76E-5), followed by deletions (2.49E-5) and insertions (3.22E-6). Nearly 70% of point mutations were nonsynonymous (Fig. 2d). Classic mutagenesis studies have previously shown that most novel mutations are deleterious or neutral14,15, which may account for the modest number of viral variants that have emerged during the pandemic in spite of the high mutation frequency we observe16.
To assess whether RNA variants are randomly distributed across the SARS-CoV-2 genome, frequencies were calculated by position. We found that variant frequencies are highly variable across positions and RNA features (Fig. 2f, Extended Data Fig. 5). Our analysis identified 779 hot spots (Extended Data Fig. 5d), or positions with elevated variant frequencies, and 272 cold spots in WT virus (Supplementary Table 2). Moreover, frequencies differed significantly among the open reading frames (ORFs) (Fig. 2e, Extended Data Fig. 6). For example, ORFs encoding structural proteins like Spike are more susceptible to RNA variants, while regions encoding enzymes appear more resistant. These results suggest that some genomic regions in SARS-CoV-2 may mutate faster or could be under higher selective pressure. To find a molecular basis for this variability, nucleotide identity was analyzed across all hot and cold spots and we observed a strong GC bias at positions with significantly elevated variant frequencies (Fig. 2h).
RNA variants in Alpha and Delta
As SARS-CoV-2 has evolved into several different lineages characterized by specific mutations and VOCs, we next examined whether variant frequencies differ between viral lineages.
Applying tARC-seq to the B.1.1.7 isolate (Alpha), we measured an RNA variant frequency of 1.51E-4 (Fig. 2b). Significantly more point mutations were observed in Alpha, particularly G>A substitutions, which occurred twice as often in Alpha as in WT (Fig. 2c). For DNA-dependent RNAPs (DdRp), these G>A errors are a signature of reduced proofreading9. We speculate that the increase in G>A events may reflect less RdRp proofreading in the Alpha lineage. While there are a few candidate mutations in Nsp12 and other replication/transcription complex interactors (Supplementary Table 1), additional studies are needed.
Position-wise calculations in Alpha again revealed a number of hot and cold spots for RNA variants (Extended Data Fig. 5d, Supplementary Table 3), of which 30.6% were shared with WT virus (Supplementary Table 4). Analyzing variant frequencies by ORFs and genomic features, there was 66.7% concordance with WT results (Extended Data Fig. 6). Genes encoding critical proteins such as Spike and RdRp were identified in both samples as having elevated and reduced variant frequencies, respectively (Fig. 2e).
The B.1.617.2 isolate (Delta) had a similar RNA variant frequency (1.43E-4) as Alpha (Fig. 2b). Despite being cultured to the same titer as previous isolates (105 to 106 pfu/mL), tARC-seq produced fewer consensus reads for Delta. While read depth was sufficient for genome-wide studies, positional variant frequencies are not reported as the tests were underpowered.
Altogether, ultra-deep sequencing across three different lineages has revealed a relatively high error frequency for SARS-CoV-2’s RdRp, despite having proofreading activity.
Viral RdRp prone to template switching
During negative strand synthesis in coronaviruses, RdRp jumps from transcription-regulatory sequences located upstream of most gene bodies (TRS-B) to a leader sequence (TRS-L) in the 5’ UTR to generate subgenomic mRNAs17. This programmed template switching is driven by sequence complementarity between TRS sequences, and it functions to add a common leader sequence to viral transcripts to enhance gene expression18. tARC-seq detected fusion transcripts in WT SARS-CoV-2 with junctions mapping to canonical TRS sites (Fig. 3a). Moreover, programmed template switching impacts RdRp fidelity as TRS flanking regions exhibit significantly higher variant frequencies in WT and Alpha virus (Fig. 3b, Extended Data Fig. 7c–d).
Non-programmed template switching has also been implicated in insertion events and the emergence of novel coronavirus strains19. Analyzing tARC-seq data, we observe many recurrent junctions outside canonical TRSs in fusion transcripts (Extended Data 7a–b) as previously reported17. Compellingly, a number of large insertions and deletions were observed in WT virus (Fig. 3d) and related lineages (Extended Data Fig. 8a), many of which appear templated from within the SARS-CoV-2 genome. We model two deletions by RdRp slippage at neighboring repeat sequences during transcription (Fig. 3e). Also shown is a large 41-nucleotide insertion (Fig. 3f), which can be modeled by microhomology-mediated template switching involving three sequential jumps between discrete genomic loci. These templated indels represent the rare scenario where RdRp realigns to the correct sequence after a template switching event. Sequence complementarity between donor and acceptor sites facilitates the jump; however, it is unclear what other features are involved in promoting template switching. As further evidence, we found that many indels are clustered around certain sequences, which we’ve termed transcription “skip sites” (Fig. 3c, Extended Data 8c, Supplementary Tables 5-6). Jumpy RdRp activity at skip sites fuels a diverse repertoire of indels detectable by tARC-seq at a single locus (Extended Data Fig. 8b). For example, the indel frequency at position 23308, pictured in Fig. 3e–f, is elevated ten-fold over the genome-wide average in both WT (g.23303: 2.97E-4) and Alpha (g.23308: 3.11E-4). Skip sites often sit adjacent to regions of microhomology (Extended Data 8d) and homopolymeric nucleotide runs (Extended Data 8e), which drive up local indel frequencies.
Non-programmed template switching drives pandemic genomic epidemiology
Signatures of aberrant RdRp template switching are present in sequences from real-world pandemic data as well (Fig. 4a). One event, a GGG to AAC substitution, defines the 20B clade (Fig. 4b) from which the Alpha, Gamma, Lambda and Omicron lineages evolved. All of these viral variants also contain lineage-specific multiple nucleotide alterations that can be modeled as single RdRp misalignment and realignment events templated from within the SARS-CoV-2 genome (Fig. 4c–e; Extended Data Fig. 9). Thus, template switching represents a major driver of virus evolution.
RNA variants in the Pfizer-BioNTech COVID-19 vaccine
The Pfizer-BioNTech COVID-19 vaccine was the first mRNA vaccine approved for use and has been an instrumental tool in our public health arsenal against SARS-CoV-220. Vaccine mRNA is the product of in vitro transcription (IVT) by T7 phage polymerase from a codon-optimized, Spike-encoding DNA construct (Extended Data Fig. 1b)21. As a DdRp, T7 polymerase also commits errors during transcription at frequencies ranging from 10−4 to 10−6[22,23]. These errors have not been studied in the context of vaccine production or vaccine-induced immunity. As vaccine mRNA is abundant and amenable to sequencing by bulk RNA consensus sequencing (ARC-seq) (Fig. 1), we characterized the frequency and spectrum of RNA variants in the Pfizer vaccine.
The overall variant frequency in vaccine mRNA is 2.34 x 10−4, or double that of WT SARS-CoV-2 (Fig. 5a). At that frequency, full-length Spike transcripts contain on average one novel variant each. The spectrum and clonality of variants in the S gene detected by (t)ARC-seq differs between vaccine and WT virus (Fig.5, Extended Data Fig. 3b), likely reflecting differences between the two RNAPs. Fewer deletions, but more insertions, were observed in vaccine mRNA (Fig. 5a). The C>T base substitution frequency is lower in the vaccine given the absence of RNA editing in vitro (Fig. 5b). Additionally, G>A transitions were more frequent compared to any of the viral isolates tested (Fig. 5b), which may reflect the intrinsic lack of proofreading activity of T7 RNAP22. Among the point mutations, 67% were nonsynonymous (Fig. 5c). Sequencing depth was more consistent across the S gene in vaccine mRNA and position-wise tests revealed a more even landscape of variant frequencies compared to viral samples (Fig. 5d–e).
RNA errors during T7 in vitro transcription
The high variant frequency in the Pfizer vaccine could stem from a number of variables, including template codon optimization, T7 polymerase biology, synthesis with modified nucleotides, IVT conditions, and vaccine packaging and storage. To address this, a series of T7 IVT reactions was performed in parallel over a range of temperatures on two different templates: (1) the native S gene from WT SARS-CoV-2, and (2) the codon-optimized Spike construct from the Pfizer vaccine. The two templates differ significantly by nucleotide content, with the modified vaccine template being 57% GC compared to 37% for the viral template. mRNA from either IVT reaction had a reduced variant frequency compared to the vaccine (Fig. 5f), but differences between the IVT reactions were apparent as well (Extended Data Fig. 10a–b). Significantly, IVT from the vaccine template produced fewer RNA variants of all types (1.06E-4) at an overall rate comparable to WT virus, suggesting that high GC content is protective against transcription errors in vitro. We observed that IVT reactions from the viral template are seven times more prone to insertion errors (4.9E-5 for insertions; 1.8E-4 overall) compared to the vaccine template, implicating low GC content in template switching (Extended Data Fig. 10a). We also found evidence of template switching in IVT transcripts (Extended Data Fig. 10d), corroborating our findings in viral isolates. Modulating the temperature during IVT did not appear to affect the variant frequency (Extended Data Fig. 10a–b).
After controlling for GC enrichment and standard T7 IVT conditions, we conclude that the intrinsic error-prone nature of T7 RNAP is the main source of vaccine variants. However, other features specific to Pfizer vaccine production, such as the use of N1-methylpseudouridine24,25, mRNA purification, liposomal packaging, vaccine freezing and storage, or the scale up for production, also contribute to the RNA variant frequencies observed in the vaccine samples..
Discussion
Herein, we describe a targeted sequencing method for detecting RNA variants in rare transcripts and low abundance samples. We have sequenced three SARS-CoV-2 isolates and established a baseline variant frequency of ~1 in 10,000 per nucleotide for the virus. While higher than other predictions4, this frequency is comparable to similar observations in poliovirus, which also utilizes an RdRp for replication but lacks an associated proofreading activity8,11,26. The error frequency estimations were previously based on the presence of a proofreading 3’-to-5’ exoribonuclease (ExoN, nsp14) in SARS-CoV-2 that is distinct from the viral RdRp27. The same proofreading activity has been implicated in promoting template switching28, which we show here is error-prone. Thus, our work highlights the promiscuous nature of SARS-CoV-2’s RdRp driven by nucleotide misincorporation and erroneous template switching, both controlled by the same exonuclease. ExoN may be a key protein involved in tuning viral evolution. Together, these results showcase the fundamental biology propelling viral diversity and evolution on a massive scale during the COVID-19 pandemic.
In conjunction with viral data, we also measured RNA variants in the Pfizer BioNTech COVID-19 vaccine using ARC-seq. At a frequency of 1 in 5,000 nucleotides, the pace of vaccine variants appears balanced against viral evolution and suggests that the majority of mRNA produced encodes variant Spike proteins. The role of vaccine heterogenicity in the immune response is currently unknown. Our data may provide insight to explain how mRNA vaccines against COVID-19 offer broader protection against novel strains upon boosting22,29–31. Vaccine variants could promote a more diverse immune repertoire, which offers benefits in the context of a rapidly evolving virus. However, other uses like cancer vaccines or mRNA drugs may require high fidelity transcription to reduce the risk of autoimmunity or improve clinical efficacy2. Identification and usage of high fidelity RNAP may be crucial for the development of future therapies. Importantly, our results build on a growing body of work promoting mRNA-based drug technologies in medicine and public health.
Finally, beyond the COVID-19 pandemic, tARC-seq has revealed many new principles concerning basic RdRp biology. RNA errors are non-random and linked to GC content, transcriptional patterns and sequence complementarity. RdRp is capable of non-programmed template switching to form structural variants, insertions and deletions, ultimately fueling virus evolution. Future research should expound on the sequence motifs and rules that regulate RNA errors and polymerase switching events as they likely afflict every corner of life. Perhaps then we can begin to understand how organisms have evolved to mitigate RNAP infidelity or learned to exploit it.
Methods
RNA extraction
All RNA samples were processed under RNase-free conditions using dedicated equipment and reagents. To maintain RNA integrity, samples were limited to ≤1 freeze-thaw cycle, kept on ice whenever possible, and not subjected to high temperatures (≥65 C) in the presence of metal cations 9. RNA integrity was confirmed via Agilent Tapestation™ prior to sequencing library preparation.
SARS-CoV-2
Ancestral SARS-CoV-2 was received from the World Reference Center for Emergeing Viruses and Arboviruses at The University of Texas Medical Branch (Galveston, TX, USA) under the direction of Drs. Scott Weaver and Kenneth Plante. Alpha variant (SARS-CoV-2, hu/USA/CA_CDC_5574/2020, Source: Centers for Disease Control and Prevention, BEI Catalogue number NR-54011) and Delta variant (Isolate hCoV-19/USA/PHC658/2021 (Lineage B.1.617.2; Delta Variant, Source: St. Jude’s Children’s Research Hospital, BEI Catalogue Number NR-55611) were received from BEI Resources. Viral stocks were prepared by infecting Vero CCL-81 cells as previously described33. Briefly, 48-72 hours post infection, supernatant from infected cultures were collected and a plaque assay was performed using Vero E6 cells to calculate viral titer. Virus was inactivated in TRIzol™ reagent before freezing at −80 C for long-term storage. RNA was exacted from thawed TRIzol preps 34 at the time of library preparation.
Pfizer-BioNTech COVID-19 vaccine
Vaccine was collected from the remains of unexpired, spent vials (LOT ER8727, EXP 07/2021) that had been stored at room temperature for <6 hours, as per the manufacturer’s recommendations for proper handling. No vaccine that could otherwise have been administered to patients was sacrificed for the purposes of this study. Vaccine samples were transferred on wet ice. Upon receipt, RNA was immediately extracted with PhenokChloroformTsoamyl Alcohol (25:24:1) (PCA) followed by ethanol precipitation. Samples were reconstituted in nuclease-free water and analyzed by Qubit Fluorometer™ and Agilent Tapestation™ prior to storage at −80 C.
Escherichia coli
Luria broth was inoculated from isolated colonies and grown for 16 hours at 37 C. The next day, overnight cultures were washed, diluted 100-fold in fresh LB, and grown at 37 to mid-log phase (OD600 ~0.4). 1 mL culture aliquots were then harvested in duplicate and placed on ice preceding RNA extraction using the RNAsnap™ protocol35. Following harvest, sample cleanup was performed with the RNA Clean & Concentrator Kit (Zymo Research) and DNase treatment (TURBO™ DNase) was applied off-column at 37 C for 1 hour. The ribosomal RNA fraction was depleted via the RiboMinus™ Transcriptome Isolation Kit for bacteria (Invitrogen™), and the resulting mRNA was concentrated by ethanol precipitation for downstream library preparation.
In vitro transcription
Two different templates were used for in vitro transcription (IVT): (I) the native SARS-CoV-2 Spike gene (Addgene 145670), and (II) the codon-optimized, GC-enriched spike-encoding construct from Pfizer-BioNTech 36,37. Both genes were expressed from bacterial expression plasmids downstream of T7 promoters. Plasmids were isolated from E. coli cultures using the QIAprep Spin Miniprep Kit™ and subjected to single-enzyme digest with SnaBI (viral template) or Mlul (vaccine template). Linearized plasmid was then cleaned up by PCA and verified by Qubit Fluorometer™ and gel electrophoresis before IVT. Reactions were performed in parallel at escalating temperatures (30, 37, 42 C) using the Hi Scribe® T7 High Yield RNA Synthesis Kit (NEB) and the ProFlex PCR System Thermal Cycler (Applied Biosystems). Starting from 200 ng of template, reactions were allowed to proceed for two hours before TURBO™ DNase treatment. Transcription products were purified by PCA for sequencing. Notably, while IVT from the vaccine template was less efficient and had lower yields, vaccine transcripts were more resistant to RNaseIII fragmentation during library preparation.
Library preparation and sequencing
Total accurate RNA consensus sequencing (ARC-seq)
1 μg of RNA was enzymatically fragmented with RNaseIII for 7 min to an average size of 450 nt 38. Following PCA cleanup, the remaining steps of library construction were guided by ARC-seq design 10. Briefly, RNA was 5’ adenylated and ligated to unique molecular identifiers (UMIs). Barcoding individual fragments before any amplification reactions downstream is critical for error correction during consensus calling. The library was then circularized and primed for rolling-circle reverse-transcription, yielding multiple conjoined copies of the original fragment. After digesting these long cDNA oligomers, the individual monomers were PCR amplified with tailed primers to add sequencing adapters and additional indexes. The final library was analyzed by Tapestation prior to paired-end sequencing on the Illumina NextSeq 550 system. Importantly, reaction conditions were optimized throughout to reduce RNA damage from heat and metal ion catalysis.
Targeted accurate RNA Consensus sequencing (tARC-seq)
For concentrated samples (≥ 100 ng/μL), fragmentation can proceed as described above. However, for low-abundance samples it is recommended to add carrier RNA up to 1 μg. For the SARS-CoV-2 experiments, a previously sequenced E. coli sample was mixed 4:1 with viral RNA and served as both the carrier and internal control. Once fragmented, the targeted libraries are prepared by the total RNA protocol up through the last indexing step. SARS-CoV-2 reads were then enriched using the COVID xGen Hybrid Capture Kit (IDT) and 7-9 cycles of post-capture PCR to generate the final library.
Data analysis
Error-correction and variant calling
Illumina BCL files were converted to Fastq and demultiplexed from the 6 nt sample barcode in the i7 index read (base masking: Y*,I6N*,Y*,Y*). Next, UMIs were extracted and appended to the read headers before converting to unaligned BAM format. Specifically, the 11 nt PCR UMI was read from the i5 index, and the 16 nt cDNA UMI was clipped from the leading 16 bases of Read 2. Reads with identical UMI tags, originating from the same RNA fragment, were grouped into families and collapsed into consensus reads using a custom python script. Consensus FASTQ sequences were aligned to the appropriate reference genome using BWA-MEM (accessions: NC_000913.3, NC_045512.2). Reads were then quality filtered, clipped, and realigned with GATK v3.8. Finally, variants were called using mpileup and tabulated via a custom R script. (Scheme S1)
Statistical information
Frequencies were calculated as variant count / total consensus nucleotides sequenced. Proportion confidence intervals (two-tailed) were calculated for each frequency and error bars represent Wilson scores of 95% confidence. To detect positions in the SARS-CoV-2 genome that have a base substitution frequency different from the sample average, we constructed a contingency table and performed Fisher’s exact test comparing each position to the genome-wide average. All positions that passed our initial filter (clonality ≤0.05, raw depth ≥50, fraction of N ≤0.05) were included in this analysis. To control the false discovery rate, p-values were adjusted using the Benjamini–Hochberg procedure. Positions with adjusted p-values <0.05 and substitution frequencies that are elevated or reduced compared to the genome-wide average were called as hot and cold spots, respectively. E. coli hybrid capture was performed on 2 biological replicates. Viral analysis was performed on 1 biological replicate per genotype. Vaccine sequencing data represents 2 vials of the same lot (n=2). In vitro experiments were performed in triplicate at 30, 37, and 42 C (n=1 per temperature).
3D protein map of variant frequencies by codon
Average RNA base substitution frequencies were calculated for each codon in the Spike protein by sum(base substitution count)/sum(adjusted depth). All positions that passed our initial filter (clonality ≤0.05, raw depth ≥50, fraction of N ≤0.05) and were sequenced at a raw depth ≥10000 were included in this analysis. The Spike protein full-length model 6vsb_1_1_1 39 was then colored based on the codon average RNA base substitution frequency using Pymol 40.
Extended Data
Table 1 |.
WT virus | Ancestral SARS-CoV-2 (Isolate USA-WA1/2020) |
---|---|
Viral variant or lineage | Virus that harbors fixed, characteristic genomic mutations compared to WT (e.g. Alpha, Delta, Omicron) |
RNA variant | Any base alteration from the WT genomic RNA sequence (e.g. G>A) |
Clonal variants | Fixed RNA alterations present at a given loci across sequenced observations (clonality > .9) |
Subclonal variants | RNA alterations present in <90% of consensus sequences but >5% |
De novo variants | A new RNA variant that arises from RNAP errors, RNA modification or damage and not from propagation of an existing variant during replication (clonality < 0.05) |
Acknowledgments
We would like to thank Susan Rosenberg, Mary Estes, Carol Gross, Peter Hotez, Jennifer Halliday, and Herman Dierick for critical reading. We also thank the Baylor Vaccine Clinic staff for supplying spent vials of Pfizer-BioNTech COVID-19 vaccine and for their dedicated service to the BCM community during the pandemic, including: Lisa Icard, MHA, BSN, RN, Director of Nursing; Tera Skeen, MSN, RN, Quality Nurse; Jennifer Johnson, MSHS, BSN, RN. The following reagent was obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate hCoV-19/USA/PHC658/2021 (Lineage B.1.617.2; Delta Variant), NR-55611, contributed by Dr. Richard Webby and Dr. Anami Patel. The following reagent was deposited by Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2 (Lineage B.1.1.7; Alpha variant), Isolate USA/CA_CDC_5574/2020, NR-54011. Ancestral WT SARS-CoV-2 was provided by the World Reference Center for Emerging Viruses and Arboviruses (WRCEVA) at the University of Texas Medical Branch. Plasmid pGBW-m4046758 was a gift from Ginkgo Bioworks & Benjie Chen (Addgene plasmid # 145670 ; http://n2t.net/addgene:145670 ; RRID:Addgene_145670). The study was supported by NIH grants DP1-AI152073 (C.H), 3R01AG061105-03S1 (O.L), 1R21CA259780 (SRK), and 1R21HG011229 (SRK); and by NSF grant DBI-2032904 (O.L.).
Footnotes
Code availability Python and R code are available on reasonable request.
Competing interests The authors declare no competing interests.
Supplementary Information is available for this paper.
Data availability
Sequencing data are available through the Sequence Read Archive under Bio Project PRJNA824595. All other data are available from the corresponding author upon reasonable request.
Main references
- 1.Snijder E. J., Decroly E. & Ziebuhr J. Chapter Three - The Nonstructural Proteins Directing Coronavirus RNA Synthesis and Processing. in Advances in Virus Research (ed. Ziebuhr J.) vol. 96 59–126 (Academic Press, 2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Sahin U., Karikó K. & Türeci Ö. mRNA-based therapeutics--developing a new class of drugs. Nat Rev Drug Discov 13, 759–780 (2014). [DOI] [PubMed] [Google Scholar]
- 3.Bradley C. C., Gordon A. J. E., Halliday J. A. & Herman C. Transcription fidelity: New paradigms in epigenetic inheritance, genome instability and disease. DNA Repair (Amst) 81, 102652 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Bar-On Y. M., Flamholz A., Phillips R. & Milo R. SARS-CoV-2 (COVID-19) by the numbers. Elife 9, e57309 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Muik A. et al. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. Science 375, 678–680 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Wang Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 592, 616–622 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Sanjuán R., Nebot M. R., Chirico N., Mansky L. M. & Belshaw R. Viral Mutation Rates. Journal of Virology 84, 9733–9748 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Moeller N. H. et al. Structure and dynamics of SARS-CoV-2 proofreading exoribonuclease ExoN. Proc Natl Acad Sci U S A 119, e2106379119 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Gout J.-F. et al. The landscape of transcription errors in eukaryotic cells. Science Advances 3, e1701484 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Reid-Bayliss K. S. & Loeb L. A. Accurate RNA consensus sequencing for high-fidelity detection of transcriptional mutagenesis-induced epimutations. Proc Natl Acad Sci U S A 114, 9415–9420 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Acevedo A., Brodsky L. & Andino R. Mutational and fitness landscapes of an RNA virus revealed through population sequencing. Nature 505, 686–690 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Traverse C. C. & Ochman H. A Genome-Wide Assay Specifies Only GreA as a Transcription Fidelity Factor in Escherichia coli. G3 (Bethesda) 8, 2257–2264 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Di Giorgio S., Martignano F., Torcia M. G., Mattiuz G. & Conticello S. G. Evidence for host-dependent RNA editing in the transcriptome of SARS-CoV-2. Sci Adv 6, eabb5813 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Eyre-Walker A. & Keightley P. D. The distribution of fitness effects of new mutations. Nat Rev Genet 8, 610–618 (2007). [DOI] [PubMed] [Google Scholar]
- 15.Sanjuán R., Moya A. & Elena S. F. The distribution of fitness effects caused by single-nucleotide substitutions in an RNA virus. Proc Natl Acad Sci U S A 101, 8396–8401 (2004). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Morales A. C. et al. Causes and Consequences of Purifying Selection on SARS-CoV-2. Genome Biol Evol 13, evab196 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Kim D. et al. The Architecture of SARS-CoV-2 Transcriptome. Cell 181, 914–921.e10 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Alonso S., Izeta A., Sola I. & Enjuanes L. Transcription Regulatory Sequences and mRNA Expression Levels in the Coronavirus Transmissible Gastroenteritis Virus. J Virol 76, 1293–1308 (2002). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Garushyants S. K., Rogozin I. B. & Koonin E. V. Insertions in SARS-CoV-2 genome caused by template switch and duplications give rise to new variants that merit monitoring. bioRxiv 2021.04.23.441209 (2021) doi: 10.1101/2021.04.23.441209. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Goel R. R. et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 374, abm0829 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Vogel A. B. et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 592, 283–289 (2021). [DOI] [PubMed] [Google Scholar]
- 22.Huang J., Brieba L. G. & Sousa R. Misincorporation by wild-type and mutant T7 RNA polymerases: identification of interactions that reduce misincorporation rates by stabilizing the catalytically incompetent open conformation. Biochemistry 39, 11571–11580 (2000). [DOI] [PubMed] [Google Scholar]
- 23.Sultana S., Solotchi M., Ramachandran A. & Patel S. S. Transcriptional fidelities of human mitochondrial POLRMT, yeast mitochondrial Rpo41, and phage T7 single-subunit RNA polymerases. J Biol Chem 292, 18145–18160 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Karikó K., Buckstein M., Ni H. & Weissman D. Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA. Immunity 23, 165–175 (2005). [DOI] [PubMed] [Google Scholar]
- 25.Nance K. D. & Meier J. L. Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines. ACS Cent. Sci. 7, 748–756 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Arnold J. J. & Cameron C. E. Poliovirus RNA-dependent RNA polymerase (3Dpol): pre-steady-state kinetic analysis of ribonucleotide incorporation in the presence of Mg2+. Biochemistry 43, 5126–5137 (2004). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Sjaarda C. P. et al. Temporal Dynamics and Evolution of SARS-CoV-2 Demonstrate the Necessity of Ongoing Viral Genome Sequencing in Ontario, Canada. mSphere 6, e00011–21 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Gribble J. et al. The coronavirus proofreading exoribonuclease mediates extensive viral recombination. PLoS Pathog 17, e1009226 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Tarke A. et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell 185, 847–859.e11 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Kim W. et al. Germinal centre-driven maturation of B cell response to mRNA vaccination. Nature (2022) doi: 10.1038/s41586-022-04527-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Muecksch F. et al. Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose. 2022.02.14.480394 (2022) doi: 10.1101/2022.02.14.480394. [DOI] [Google Scholar]
Methods references
- 32.Hadfield J. et al. Nextstrain: real-time tracking of pathogen evolution. Bioinformatics 34, 4121–4123 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Harcourt J. et al. Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States. Emerg Infect Dis 26, 1266–1273 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Rio D. C., Ares M., Hannon G. J. & Nilsen T. W. Purification of RNA Using TRIzol (TRI Reagent). Cold Spring Harb Protoc 2010, pdb.prot5439 (2010). [DOI] [PubMed] [Google Scholar]
- 35.Stead M. B. et al. RNAsnap™: a rapid, quantitative and inexpensive, method for isolating total RNA from bacteria. Nucleic Acids Res 40, e156 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Reverse Engineering the source code of the BioNTech/Pfizer SARS-CoV-2 Vaccine. Bert Hubert’s writings https://berthub.eu/articles/posts/reverse-engineering-source-code-of-the-biontech-pfizer-vaccine/ (2020).
- 37.NAalytics. Assemblies-of-putative-SARS-CoV2-spike-encoding-mRNA-sequences-for-vaccines-BNT-162b2-and-mRNA-1273. (2021).
- 38.Ares M. Fragmentation of Whole-Transcriptome RNA Using E. coli RNase III. Cold Spring Harb Protoc 2013, pdb.prot074369 (2013). [DOI] [PubMed] [Google Scholar]
- 39.Woo H. et al. Developing a Fully Glycosylated Full-Length SARS-CoV-2 Spike Protein Model in a Viral Membrane. J. Phys. Chem. B 124, 7128–7137 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Schrodinger. The PyMOL Molecular Graphics System, Version 2.5.2. (2018).
- 41.DataBase Center for Life Science. 201306 needle syringe. (2017).
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Sequencing data are available through the Sequence Read Archive under Bio Project PRJNA824595. All other data are available from the corresponding author upon reasonable request.